286 related articles for article (PubMed ID: 22965928)
1. Comparative rates of adverse events with different formulations of intravenous iron.
Okam MM; Mandell E; Hevelone N; Wentz R; Ross A; Abel GA
Am J Hematol; 2012 Nov; 87(11):E123-4. PubMed ID: 22965928
[TBL] [Abstract][Full Text] [Related]
2. Review of available intravenous iron preparations in hemodialysis.
Palmer K; Cameron K; Battistella M
CANNT J; 2013; 23(2):51-4; quiz 55-6. PubMed ID: 24069699
[No Abstract] [Full Text] [Related]
3. A randomized comparison of ferumoxytol and iron sucrose for treating iron deficiency anemia in patients with CKD.
Macdougall IC; Strauss WE; McLaughlin J; Li Z; Dellanna F; Hertel J
Clin J Am Soc Nephrol; 2014 Apr; 9(4):705-12. PubMed ID: 24458078
[TBL] [Abstract][Full Text] [Related]
4. Should intravenous iron be upfront therapy for iron deficiency anemia?
Auerbach M
Pediatr Blood Cancer; 2011 Apr; 56(4):511-2. PubMed ID: 21298731
[No Abstract] [Full Text] [Related]
5. Comparative Short-term Safety of Sodium Ferric Gluconate Versus Iron Sucrose in Hemodialysis Patients.
Brookhart MA; Freburger JK; Ellis AR; Winkelmayer WC; Wang L; Kshirsagar AV
Am J Kidney Dis; 2016 Jan; 67(1):119-27. PubMed ID: 26385819
[TBL] [Abstract][Full Text] [Related]
6. Parenteral iron therapy options.
Silverstein SB; Rodgers GM
Am J Hematol; 2004 May; 76(1):74-8. PubMed ID: 15114602
[TBL] [Abstract][Full Text] [Related]
7. Low-molecular weight iron dextran and iron sucrose have similar comparative safety profiles in chronic kidney disease.
Auerbach M; Al Talib K
Kidney Int; 2008 Mar; 73(5):528-30. PubMed ID: 18274543
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of intravenous and oral iron in chronic kidney disease.
Agarwal R; Kusek JW; Pappas MK
Kidney Int; 2015 Oct; 88(4):905-14. PubMed ID: 26083656
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial.
Birgegård G; Henry D; Glaspy J; Chopra R; Thomsen LL; Auerbach M
Pharmacotherapy; 2016 Apr; 36(4):402-14. PubMed ID: 26927900
[TBL] [Abstract][Full Text] [Related]
10. Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron Products.
Wang C; Graham DJ; Kane RC; Xie D; Wernecke M; Levenson M; MaCurdy TE; Houstoun M; Ryan Q; Wong S; Mott K; Sheu TC; Limb S; Worrall C; Kelman JA; Reichman ME
JAMA; 2015 Nov; 314(19):2062-8. PubMed ID: 26575062
[TBL] [Abstract][Full Text] [Related]
11. Acute injury with intravenous iron and concerns regarding long-term safety.
Bishu K; Agarwal R
Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S19-23. PubMed ID: 17699372
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial comparing ferric carboxymaltose and iron sucrose for treatment of iron deficiency anemia due to abnormal uterine bleeding.
Mahey R; Kriplani A; Mogili KD; Bhatla N; Kachhawa G; Saxena R
Int J Gynaecol Obstet; 2016 Apr; 133(1):43-8. PubMed ID: 26868063
[TBL] [Abstract][Full Text] [Related]
13. Effects of Total Dose Infusion of Iron Intravenously in Patients With Acute Heart Failure and Anemia (Hemoglobin < 13 g/dl).
Kaminsky BM; Pogue KT; Hanigan S; Koelling TM; Dorsch MP
Am J Cardiol; 2016 Jun; 117(12):1942-6. PubMed ID: 27161817
[TBL] [Abstract][Full Text] [Related]
14. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
[TBL] [Abstract][Full Text] [Related]
15. Intravenous iron sucrose versus oral iron in treatment of iron deficiency anemia in pregnancy: a randomized clinical trial.
Kochhar PK; Kaundal A; Ghosh P
J Obstet Gynaecol Res; 2013 Feb; 39(2):504-10. PubMed ID: 22925176
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intravenous iron sucrose versus low-molecular-weight iron dextran in chronic kidney disease.
Sinha S; Chiu DY; Peebles G; Kolakkat S; Lamerton E; Fenwick S; Kalra PA
J Ren Care; 2009 Jun; 35(2):67-73. PubMed ID: 19432851
[TBL] [Abstract][Full Text] [Related]
17. Protocol and baseline data for a prospective open-label explorative randomized single-center comparative study to determine the effects of various intravenous iron preparations on markers of oxidative stress and kidney injury in chronic kidney disease (IRON-CKD).
Ziedan A; Bhandari S
Trials; 2019 Apr; 20(1):194. PubMed ID: 30947751
[TBL] [Abstract][Full Text] [Related]
18. Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator.
Stein J; Dignass A; Chow KU
Curr Med Res Opin; 2012 Feb; 28(2):241-3. PubMed ID: 22181342
[TBL] [Abstract][Full Text] [Related]
19. TIDILAP: Treatment of iron deficiency in lipoprotein apheresis patients --A prospective observational multi-center cohort study comparing efficacy, safety and tolerability of ferric gluconate with ferric carboxymaltose.
Schatz U; Illigens BM; Siepmann T; Arneth B; Siegert G; Siegels D; Heigl F; Hettich R; Ramlow W; Prophet H; Bornstein SR; Julius U
Atheroscler Suppl; 2015 May; 18():199-208. PubMed ID: 25936327
[TBL] [Abstract][Full Text] [Related]
20. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
